TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 16 and less than 51 years of age~* Must weigh at least 100 lbs with a body mass index of at least 18 and less than 30~* Must have up to four of their back teeth (third-molars) pulled~Exclusion Criteria:~* Cannot be allergic to acetaminophen (Tylenol)~* Cannot be pregnant (or planning to be pregnant) or nursing a baby~* Cannot have any other medical conditions that the investigator determines might compromise your safety or the study results

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- ACE-1000 (Type: EXPERIMENTAL): 1000 mg Acetaminophen Caplet
- ACE-650 (Type: ACTIVE_COMPARATOR): 650 mg Acetaminophen Caplet
- ACE-0 (Type: PLACEBO_COMPARATOR): 0 mg Acetaminophen Caplet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of OCD~* Currently on a stable and adequate dose of an SRI~* Sufficient severity of symptoms to warrant additional augmentation treatment~Exclusion Criteria:~* Medical or psychiatric conditions that would make participation in the study unsafe~* Currently receiving psychotherapy elsewhere at the time of study entry~* Previously (within 12 weeks prior to study entry) attended 8 or more sessions of EX/RP within a 2-month period or received at least 4 weeks of antipsychotic augmentation while on an adequate SRI dose~* Currently being treated with an SRI for the first time and has not yet responded, but has not tried another SRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Participants will receive treatment with risperidone
- 2 (Type: ACTIVE_COMPARATOR): Participants will receive exposure and ritual prevention therapy (EX/RP)
- 3 (Type: PLACEBO_COMPARATOR): Participants will receive treatment with the placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of ASP2151 in Herpes Zoster Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~(1) Patients who have a rash associated with herpes zoster, and who can start receiving the study drug within 72 hours after onset of the rash~Exclusion Criteria:~1. Patients who are not expected to have an adequate response to oral antiviral medication~2. An extreme decline in immune function~3. Presence of serious complications~4. Patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent:~   * AST or ALT ≥ 2.5 x upper limit of normal~  * Platelet count \< lower limit of normal~  * Serum creatinine ≥ 1.5 mg/dL~  * Creatinine clearance \< 50 mL/min~5. Current or previous history of malignant tumor within 5 years before informed consent~6. Diagnosis of autoimmune disease~7. Evidence of bone marrow suppression

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- ASP2151(200 mg) (Type: EXPERIMENTAL): once daily
- ASP2151(400mg) (Type: EXPERIMENTAL): once daily
- valaciclovir (Type: EXPERIMENTAL): 1000 mg three times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vitamin D Supplementation in Bariatric Surgery Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: Adult female obese patients undergoing either Roux-en Y gastric bypass or sleeve gastrectomy at The Methodist Hospital may participate in the study. Obese patients with a body mass index (BMI) \> 40 or BMI \>35 with a co-morbidity will be eligible.~-~Exclusion Criteria:Subjects will be excluded if they have evidence of vitamin D deficiency (\< 20 ng/mL), hypercalcemia (calcium \> 2.63 mmol/L), hypocalcemia (calcium \< 1.75 mmol/L), renal insufficiency (GFR \< 50 ml/min), or a history of primary hyperparathyroidism or renal tubular acidosis.Participants will be excluded if they take medications that interfere with vitamin D metabolism, have significant sun exposure, plan to travel to sunny climates during the study, or a history of hypercalcemia.~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Vitamin D3 and Calcium (Type: EXPERIMENTAL): Dietary supplement of vitamin D3 and calcium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a confirmed diagnosis of multiple sclerosis and at randomisation have entered the secondary progressive stage. Steady progression rather than relapse must be the major cause of increasing disability in the preceding 2 years. Progression can be evident from either an increase of at least one point on the EDSS or clinical documentation of increasing disability.~* EDSS 4.0 - 6.5 inclusive~* Women of childbearing age will be required to use appropriate methods of contraception to avoid the unlikely teratogenic effects of simvastatin.~* Able to give written informed consent~* 18 - 65 years~Exclusion Criteria:~* Unable to give informed consent~* Primary progressive MS~* Those that have experienced a relapse or have been treated with steroids (both i.v. and oral) within 3 months of the screening visit. These patients may undergo a further screening visit once the 3 month window has expired and may be included if no steroid treatment has been administered in the intervening period.~* Patient is already taking or is anticipated to be taking a statin.~* Any medications that unfavourably interact with statins: fibrates, nicotinic acid, cyclosporine, azole anti-fungal preparations, macrolideantibiotics, protease inhibitors, nefazodone, verapamil, amiodarone, large amounts of grapefruit juice or alcohol abuse.~* The use of immunosuppressants (e.g. azathioprine, methotrexate, cyclosporine) or disease modifying treatments (avonex, rebif, betaferon, glatiramer) within the previous 6 months.~* The use of mitoxantrone if treated within the last 12 months.~* If the patient has ever been treated with alemtuzumab.~* If screening levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) or creatine kinase (CK) are three times the upper limit of normal patients should be excluded.~* Patient unable to tolerate baseline scan or scan not of adequate quality for analysis (e.g. too much movement artefact).~* If a female patient is pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Simvastatin 80mg OD
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* subjects aged from 6-11 months old at the date of recruitment;~* with informed consent signed by parent(s) or guardians;~* parent(s) or guardians are able to attend all planned clinical appointments and comply with all study instructions;~* subjects not receive any vaccination within 14 days at the date of recruitment;~* subjects have not been vaccinated with EV71 vaccine, seasonal flu vaccine;~* subjects with no medical history of EV71 infection;~* axillary temperature ≤37.0℃~Exclusion Criteria:~* subject who has a medical history with Hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness;~* allergic to any ingredient of vaccine or with allergy history to any vaccine;~* subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of steroid hormone);~* administration of immunoglobulins within 30 days prior to this study;~* acute febrile disease(temperature ≥ 37.0°C) or infectious disease;~* have a clearly diagnosed history of thrombocytopenia or other coagulopathy,~* may cause contraindications for subcutaneous injection;~* any serious chronic illness, acute infectious diseases, or respiratory diseases;~* severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications;~* any kind of infectious, purulent, or allergic skin diseases;~* any other factor that makes the investigator determines the subject is unsuitable for this study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 11 Months
- Healthy Volunteers: t

Study Arms:
- experimental group (Type: EXPERIMENTAL): 378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.
- control group A (Type: ACTIVE_COMPARATOR): 378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).
- control group B (Type: ACTIVE_COMPARATOR): 378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects age 18 years and older with stable plaque psoriasis of duration of at least 6 months.~* Subject must be currently using a stable dose, with stable disease severity, of a single non-biologic systemic psoriasis medication (methotrexate or acitretin) for at least 2 months.~* Subject must be planning to continue current systemic agent, and standard of care monitoring for that medication~* All labs required for methotrexate or acitretin will be done according to standard of care.~* If a woman, before entry she must be: Postmenopausal, or practicing a highly effective method of birth control~* Women of childbearing potential must have a negative urine pregnancy test prior to randomization~* Subject must be able and willing to provide written informed consent to participate.~Exclusion Criteria:~* Non-plaque psoriasis (pustular, erythrodermic, or guttate).~* Use of excluded therapies: phototherapy use currently or in the 4 weeks prior to baseline, use of more than 1 systemic therapy in the 2 months prior to baseline, use of topical steroid, tar preparation, or vitamin D analog in the 4 weeks prior to baseline.~* Subjects who are currently taking or have taken in the past 60 days, for any reason, any medication that, in the opinion of the investigator, suppressed the immune response. This may include but is not limited to systemic steroids, azathioprine, cyclosporine, FK506, mycophenolate mofetil, mycophenolic acid, etanercept, adalimumab, infliximab, ustekinumab, cimzia, or any other biologic agent targeted to any cell or cytokine in the immune system.~* Subjects with any use at any time in the past of Taclonex topical suspension or Taclonex ointment~* Subjects who are pregnant, nursing, or plan on becoming pregnant during the course of the study.~* Presence of any unstable medical or psychiatric condition that, in the opinion of the investigator, could impair subject compliance.~* Subject has any active infection within 30 days prior to baseline.~* Known or suspected disorders of calcium metabolism~* Known or suspected severe kidney or liver disease.~* Known or suspected hypersensitivity to component(s) of the investigational products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taclonex topical suspension (Type: OTHER): Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Danish Osteoporosis Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women aged 45-58 years with an intact uterus~* Three to 24 month past last menstrual bleeding~* Hysterectomised women aged 45-52 years and having elevated FSH~Exclusion Criteria:~* Metaboliv bone disease including osteoporosis defined as non-traumatic vertebral fractures on X-ray~* Current estrogen use or estrogen use within the past three month~* Current or past treatment with glucocorticoids for more than 6 month~* Current or past malignancy~* Newly diagnosed or uncontrolled chronic disease~* Alcohol or drug addiction

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 58 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~•Confirmed diagnosis of PV according to the 2008 World Health Organization criteria, palpable spleen, Resistant to or intolerant of hydroxyurea, ECOG performance status of 0, 1 or 2; did not have access to a comparable or satisfactory alternative treatment~Exclusion Criteria:~•Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral infection requiring treatment, Active malignancy within the past 5 years, except treated cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin, with no evidence for recurrence in the past 3 years., Women who were pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy subjects who have completed study V48P7~Exclusion Criteria:~* acute illness at day of immunization~* general decrease in resistance~* progressive neurological disorders~* history of febrile or afebrile convulsions~* major congenital defects~* serious chronic illness~* hypersensitivity to study vaccine~* treatment with immunosuppressants or systemic corticosteroids, immunoglobulins, whole blood or plasma derivates

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 68 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Blood draw only, no vaccine
- Arm 2 (Type: ACTIVE_COMPARATOR): Blood draw only, no vaccine
- Arm 3 (Type: ACTIVE_COMPARATOR): Blood draw only, no vaccine
- Arm 4 (Type: ACTIVE_COMPARATOR): Blood draw only, no vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age≧20 years old~2. Life expectancy≧3 months~3. Eastern Cooperative Oncology group (ECOG) score 0\~2~4. Cytologically-or histologically-confirmed non-small cell lung cancer（NSCLC)~5. Patients with clinical TNM classification of Malignant Tumours (TNM) stage IV...~Exclusion Criteria:~1. Patients with history of cardiovascular disease, including uncontrolled hypertension, congestive heart failure, myocardial infarction, angina pectoris, coronary artery disease, uncontrolled arrhythmia , previous history of encephalopathy within the past six months of screening period~2. Patients with HIV, HTLV or active tuberculosis~3. Women who are pregnant or breast-feeding~4. Patients with drug or other substance abuse~5. Patients with any other major disease, serious organ failure or patients unfit for participating in the trial (by the investigator's judgment)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: EXPERIMENTAL): 26 patients who has successfully undergone the screening criteria will be enrolled for treatment. Immune Killer Cells (IKC) will be administered through Intravenous Injection (I.V.) Frequency: One injection per week, twenty-four injections on-treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained from the subject/ from the parent/ guardian of the subject.~* Subjects who completed the full course of primary vaccination.~Exclusion Criteria:~* Immunosuppression caused by the administration of parenteral steroids or chemotherapy.~* Any confirmed or suspected human immunodeficiency virus (HIV) infection.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Henogen Hepatitis B vaccine for uremic patients
- 2 (Type: ACTIVE_COMPARATOR): Fendrix hepatitis B vaccine for uremic patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant has a qualifying ELX/TEZ/IVA-responsive CFTR mutation and does not have an exclusionary CFTR mutation~* Forced expiratory volume in 1 second (FEV1) value \>=40% and \<=100% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* History of solid organ or hematological transplantation~* Clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.
- ELX/TEZ/IVA (Type: EXPERIMENTAL): Participants 6 to less than (\<) 12 years of age and weighing \<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete